To investigate the effects of enoxaparin and fondaparinux in anticoagulant therapy for re-pregnant women with recurrent miscarriage.

A total of 66 re-pregnant women with recurrent miscarriage and hypercoagulable state who were admitted to Third People’s Hospital of Anyang from June 2016 to June 2020 were selected for research. All included subjects had complete clinical data, volunteered to cooperate with the study and signed informed consent. Using random number table method, they were divided into observation group and control group, with 33 patients in each group. Patients in the control group was treated with enoxaparin for anticoagulation therapy during pregnancy, and the observation group was treated with fondaparinux sodium therapy. The pregnancy outcomes and adverse reactions between the two groups were compared.

The live birth rate, the incidence of fetal growth restriction (FGR), the fetal loss rate in the second trimester, preeclampsia rate, placental abruption rate and spontaneous abortion rate in the second trimester were compared between the two groups, P>0.05, but the weight of newborns in the observation group was greater than that of the control group (P<0.05); the skin reaction rate, subcutaneous ecchymosis hematoma rate and transaminase elevation rate of the observation group were lower than those of the control group (P<0.05), the bleeding rate of oral and nasal mucosa, the thrombocytopenia rate, postpartum hemorrhage rate and the prolongation rate of activated partial thromboplastin time (APTT) were compared between the two groups,P>0.05.

For patients with recurrent miscarriage and re-pregnancy with blood hypercoagulability, it is very important to choose the appropriate anticoagulant therapy in pregnancy, sulfonidagandecane sodium can improve the body mass index of newborn compared with enoxaparin, and the safety is good.

Miscarriage; Recurrent; re-pregnancy; Enoxaparin; Fondaparinux